Clinical Trial

Effects of Dapagliflozin on Progression of Alport Syndrome

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 5, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Recently, a series of large clinical trials have confirmed the cardio-renal protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors. but few patients with hereditary nephritis were included in these studies. This study is to evaluate the effects of dapagliflozin on slowing kidney disease progression in patients with Alport syndrome.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-17; most recent amendment 2024-09-01.
Status change: Recruiting → Active, Not Recruiting 2024-07-30
Trial Details
NCT Number NCT06226896
Lead Sponsor Nanjing University School of Medicine
Conditions Alport Syndrome
Enrollment 222 participants
Start Date 2023-11-15
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-05